Phase
Condition
Circulation Disorders
Williams Syndrome
Vascular Diseases
Treatment
Potassium Citrate
Dietary Counselling
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Provides signed and dated informed consent form
Diagnosis of hypertension (either on treatment; or not on treatment with anambulatory blood pressure monitor (ABPM)- daytime systolic blood pressure (SBP) > 140 or diastolic blood pressure (DBP) > 90)
Male or female, aged 18 and greater (women of child bearing potential must usehighly effective contraception (e.g. combined oral contraceptives, patch, vaginalring, injectables, and implants; intrauterine device (IUD) or intrauterine system (IUS); vasectomy of male partner and tubal ligation)
24-Hour Urine K < 60 mmol/day
Exclusion
Exclusion Criteria:
Serum Potassium < 3.3 or > 5.1 mmol/L
Glomerular Filtration Rate < 45 ml/min/1.73m2
Primary hyperaldosteronism
Pregnancy or lactation
Psychiatric disorder which, in the opinion of the investigator, would interfere withthe study, or inability to give consent
Severe Liver disease
Metabolic Alkalosis (HCO3 > 32 mmol/L)
Exclude patients who need to be started on renin-angiotensin-aldosterone blockade inthe first 3 months
Gastrointestinal disorder (e.g. delayed gastric emptying, dysphagia,oesophageal/gastric/duodenal ulcer)
Presence of cardiac disease (sever myocardial damage, heart failure, or clinicalchanges in congestive heart failure, ejection fraction <35%)
Uncontrolled diabetes mellitus (HbA1C >12%)
Acute dehydration
Extensive tissue damage (burns)
Increased hypersensitivity to potassium (e.g. paramyotonia congenital or adynamiaepisodica hereditaria)
Patients taking other potassium supplements for another indication (eg. kidneystones)
Acidosis (pH<7.11)
Adrenal insufficiency
Allergies to any of the investigational product ingredients (medicinal and non-medicinal)
Patients on any of the following medications should be on a stable dose: angiotensinconverting enzyme (ACE) inhibitors, angiotensin II receptor blockers, beta-blockers,mineralocorticoid receptor antagonists, amiloride, non steroidal antiinflammatorydrugs (NSAIDs), beta-blockers, digoxin, and heparin
Study Design
Study Description
Connect with a study center
Ottawa Hospital Research Institute
Ottawa, Ontario K1H 1A2
CanadaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.